Journal of the American Academy of Child & Adolescent Psychiatry
SPECIAL COMMUNICATIONTreatment Guidelines for Children and Adolescents With Bipolar Disorder
Section snippets
Limitations of DSM-IV Criteria
There is continued debate over the appropriateness of DSM-IV criteria for classifying BPD in children and young adolescents (Biederman et al., 2000a, Findling et al., 2001). For these guidelines, we have used DSM-IV criteria, acknowledging that the current DSM-IV criteria for mania were developed for adults and are frequently difficult to apply to children. Identifying episode onset and offset can be difficult because many children with BPD present with frequent daily mood swings that have been
SECTION II: ACUTE PHASE MEDICATION TREATMENT FOR BPD
These medication treatment algorithms were developed for the acute phase treatment of children and adolescents ages 6 to 17 years who meet DSM-IV criteria for BPD-I, manic or mixed episode. In the development of this algorithm, the consensus panel established four levels of evidence (A-D) that provided the guiding principle for the stages and branching within the treatment algorithm. These levels were as follows: level A data consisted of randomized, controlled clinical trials in children;
Stage 1: Monotherapy
Monotherapy with the traditional mood stabilizers lithium, divalproex, and carbamazepine and the atypical antipsychotics olanzapine, quetiapine, and risperidone was determined to be first-line treatment. Although lithium has had the most controlled study in children and adolescents with BPD (Brumback and Weinberg, 1977, DeLong, 1990, Geller et al., 1998a, Gram and Rafaelsen, 1972, Lena et al., 1978, McIntyre et al., 2003), some limitations include small sample size and methodological problems.
Stage 1: Mood Stabilizer Plus Atypical Antipsychotic
For children with BPD-I, manic or mixed with psychosis, it was recommended that initial treatment should be a combination of a traditional mood stabilizer (lithium, divalproex, or carbamazepine) and an atypical antipsychotic. As evidence, lithium plus an adjunctive antipsychotic in an open trial (Kafantaris et al., 2001a) (level C) was shown to demonstrate significant improvement for adolescents with acute mania and psychosis. Divalproex plus an atypical antipsychotic or carbamazepine plus an
SECTION III: TREATMENT OF COMORBID PSYCHIATRIC DISORDERS
As described in the section on assessment, most children and adolescents with BPDs have other coexisting (comorbid) psychiatric disorders, particularly ADHD, oppositional defiant disorder, conduct disorder, anxiety disorder, and, during adolescence, substance abuse. In this section, the treatment of these comorbid disorders is described. However, it is important to emphasize that there are very few controlled studies for the treatment of comorbid disorders in youths with BPD and that almost all
SECTION IV: MAINTENANCE/CONTINUATION TREATMENT
The basic goals of maintenance treatment include prevention of relapse and recurrence; reduction of subthreshold symptoms, suicide risks, affective cycling, and mood instability; reduction of vocational and social morbidity; and promotion of wellness. At present, it appears that the agents that help patients get well are the same ones that keep them well. Whereas lithium, divalproex sodium, and carbamazepine have been the agents most commonly used to treat children and adolescents with BPD (
REFERENCES (135)
- et al.
Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. American Academy of Child and Adolescent Psychiatry
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Pediatric mania: a developmental subtype of bipolar disorder?
Biol Psychiatry
(2000) - et al.
Fluoxetine for the treatment of childhood anxiety disorders
J Am Acad Child Adolesc Psychiatry
(2003) - et al.
Electroconvulsive therapy in adolescents: similarities to and differences from adults
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
Fetal alcohol syndrome: neuropsychiatric phenomics
Neurotoxicol Teratol
(2003) - et al.
Lamotrigine in adolescent mood disorders
J Am Acad Child Adolesc Psychiatry
(2003) - et al.
Clinical implications of pervasive manic symptoms in children
Biol Psychiatry
(2003) - et al.
Scaling structured interview data: a comparison of two methods
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
Psychiatric phenomenology of child and adolescent bipolar offspring
J Am Acad Child Adolesc Psychiatry
(2000) - et al.
Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD
J Am Acad Child Adolesc Psychiatry
(2002)
Quetiapine as adjunctive treatment for adolescent mania associated with bipolar disorder
J Am Acad Child Adolesc Psychiatry
An open label study of gabapentin in the treatment of acute mania
J Psychiatr Res
A double-blind pilot study of risperidone in the treatment of conduct disorder
J Am Acad Child Adolesc Psychiatry
Aripiprazole in pediatric conduct disorder: a pilot study
Eur Neuropsychopharmacol
Combination lithium and divalproex sodium in pediatric bipolarity
J Am Acad Child Adolesc Psychiatry
Risperidone treatment for juvenile bipolar disorder: a retrospective chart review
J Am Acad Child Adolesc Psychiatry
Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency
J Am Acad Child Adolesc Psychiatry
Child and adolescent bipolar disorder: a review of the past 10 years
J Am Acad Child Adolesc Psychiatry
Prepubertal and young adolescent bipolarity versus ADHD: assessment and validity using the WASH-U-KSADS, CBCL, and TRF
J Affect Disord
Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections
J Am Acad Child Adolesc Psychiatry
Youth suicide risk and preventive interventions: a review of the past 10 years
J Am Acad Child Adolesc Psychiatry
The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder
J Am Acad Child Adolesc Psychiatry
Parent and child contributions to diagnosis of mental disorder: are both informants always necessary?
J Am Acad Child Adolesc Psychiatry
Adjunctive antipsychotic treatment of adolescents with bipolar psychosis
J Am Acad Child Adolesc Psychiatry
Lithium treatment of acute mania in adolescents: a large open trial
J Am Acad Child Adolesc Psychiatry
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data
J Am Acad Child Adolesc Psychiatry
Bipolar disorder and comorbid conduct disorder in childhood and adolescence
J Am Acad Child Adolesc Psychiatry
Combination pharmacotherapy in children and adolescents with bipolar disorder
Biol Psychiatry
Effect size of lithium, divalproex sodium and carbamazepine in children and adolescents with bipolar disorder
J Am Acad Child Adolesc Psychiatry
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial
J Am Acad Child Adolesc Psychiatry
Integrated family and cognitive-behavioral therapy for adolescent substance abusers: a stage I efficacy study
Drug Alcohol Depend
Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course
J Am Acad Child Adolesc Psychiatry
Nonpharmacological response in hospitalized children with conduct disorder
J Am Acad Child Adolesc Psychiatry
Cognitive-behavioral psychotherapy for children and adolescents with OCD: a review and recommendations for treatment
J Am Acad Child Adolesc Psychiatry
Cognitive-behavioral psychotherapy for children and adolescents with posttraumatic stress disorder after a single-incident stressor
J Am Acad Child Adolesc Psychiatry
Pharmacologic agents for the treatment of acute bipolar mania
Biol Psychiatry
Lithium in children of lithium-responding parents
Psychiatr Res
Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy
Biol Psychiatry
Antimicrobial-induced mania (antibiomania): a review of spontaneous reports
J Clin Psychopharmacol
Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults
J Am Acad Child Adolesc Psychiatry
Consensus development conference on antipsychotic drugs and obesity and diabetes
Diabetes Care
Effects of medical interventions on suicidal behavior. Summary and conclusions
J Clin Psychiatry
Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders
J Clin Psychiatry
Systematic chart review of the pharmacologic treatment of comorbid attention deficit hyperactivity disorder in youth with bipolar disorder
J Child Adolesc Psychopharmacol
Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young
J Child Adolesc Psychopharmacol
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder: current concepts in the validity, diagnosis and treatment of paediatric bipolar disorder
Int J Neuropsychopharmacol
Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder
Arch Gen Psychiatry
A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder
Arch Gen Psychiatry
Depression and suicide in children and adolescents
Pediatr Rev
Cited by (424)
A systematic review and network meta-analysis on comparative efficacy, acceptability, and safety of treatments in acute bipolar mania in youths
2024, Journal of Affective DisordersBipolar and related disorders
2023, Encyclopedia of Mental Health, Third Edition: Volume 1-3Elevation of C-reactive protein in adolescent bipolar disorder vs. anxiety disorders
2022, Journal of Psychiatric ResearchMental health in adolescence (II). Psychosis and bipolar disorder
2022, Medicine (Spain)Outcome Findings and Issues in Psychotherapy With Children and Adolescents: Internalizing Disorders
2022, Comprehensive Clinical Psychology, Second Edition
Disclosure: Dr. Kowatch has received research support from Astra-Zeneca and Bristol-Myers Squibb, is on the advisory boards of GlaxoSmithKline and Janssen, and is on the speaker's bureaus of Abbott, AstraZeneca, and Janssen. Dr. Wagner has received research support from Abbott, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Organon, and Pfizer; is on the advisory boards of Abbott Laboratories, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen, Jazz Pharmaceuticals, Novartis, Ortho-MacNeil, Otskua, Pfizer, UCB Pharma, and Wyeth-Ayerst; and serves on the speaker's bureaus of Abbott Laboratories, Eli Lilly, Forrest Laboratories, GlaxoSmithKline, Janssen, Novartis, and Pfizer. Dr. Findling has received research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, Johnson & Johnson, Eli Lilly, New River, Novartis, Otsuka, Pfizer, Shire, Solvay, and Wyeth and is a consultant for AstraZeneca, Best Practices, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, New River, Novartis, Otsuka, Pharmastar, PPD, Pfizer, and Shire. The other authors have no financial relationships to disclose.
WORKGROUP MEMBERS/CONTRIBUTORS
David Axelson, M.D., Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh; Joseph Biederman, M.D., Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, and Harvard Medical School, Boston; Gabrielle Carlson, M.D., Department of Psychiatry, Stony Brook University-Putnam Hall, Stony Brook, NY; Kiki Chang, M.D., Pediatric Mood Disorders Clinic, Stanford University School of Medicine, Stanford, CA; Kristen Clausen, Child and Adolescent Bipolar Foundation member; Dorie Geraci, M.S., R.N., Child and Adolescent Bipolar Foundation member; Melissa P. DelBello, M.D., Bipolar and Psychotic Disorders Research Program, University of Cincinnati College of Medicine; Paul E. Keck, Jr., M.D., Department of Psychiatry, University of Cincinnati College of Medicine; Ellen Leibenluft, M.D., Mood and Anxiety Program, National Institute of Mental Health, National Institutes of Health/DHHS, Bethesda, MD (Dr. Leibenluft participated in this meeting in a personal capacity and not as a representative of NIH); Robert Hirschfeld, M.D., Department of Psychiatry and Behavioral Sciences, University of Texas-Medical Branch, Galveston; Vivian Kafantaris, M.D., Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY; Demitri Papolos, M.D., Albert Einstein College of Medicine, Bronx, NY; Mani Pavuluri, M.D., Center for Cognitive Medicine, University of Illinois at Chicago; Mark Riddle, M.D., Department of Psychiatry and Behavioral Science, Johns Hopkins Hospital, Baltimore; Russell Scheffer, M.D., Children's Hospital of Wisconsin, Milwaukee; Lori Wiener, Ph.D., Child and Adolescent Bipolar Foundation member, Evanston, IL; Elizabeth Weller, M.D., University of Pennsylvania, Children's Hospital of Philadelphia; Janet Wozniak, M.D., Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, Boston.
Dr. Gaye Carlson provided very helpful professional support and Mrs. Diane Norton provided invaluable administrative assistance for this project.
This project was sponsored by the Child and Adolescent Bipolar Foundation and supported by unrestricted educational grants from Abbott Laboratories, AstraZeneca Pharmaceuticals, Eli Lilly and Company, Forest Pharmaceuticals, Janssen Pharmaceutical, Novartis, and Pfizer.
Article Plus (online only) materials for this article appear on the Journal's Web site: www.jaacap.com.
Workgroup members/contributors are listed before the references.
Correspondence to Dr. Kowatch, P.O. Box 570559, 7261 Medical Science Building, 231 Albert Sabin way, Cincinnati, OH 45267-0559; e-mail: [email protected].